Cancer/testis antigens for therapeutic use.
Since van der Bruggen and colleagues first identified specific human tumour-associated antigens of the MAGE family, numerous potential immunotherapeutic targets have been discovered, often belonging to the so-called cancer/ testis gene family. Several members of this group have been described as immunogenic and have been utilised in clinical trials. In a search for interesting targets within this family, our laboratory has focussed its works for a number of years on two novel cancer/testis antigens called T21 and HAGE. In this article, we will focus our discussion on their levels of expression in a wide variety of both normal and cancer tissues, their possible role in tumour cell development and proliferation, and their immunogenic potential.
The John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, UK. morgan.mathieu2@ntu.ac.uk
M G
MG
Mathieu
A K
AK
Miles
G
G
Li
S E B
SE
McArdle
R C
RC
Rees
D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D002874:Chromosome Mapping; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008113:Liver Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000276:immunology; D008297:Male; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology*; D013737:Testis / Q000276:immunology; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000276:immunology
D000951:Antigens, Neoplasm